Eisai eyes long game for Leqembi amid ‘dramatically’ increasing patient use
Full US approval of Biogen and Eisai’s Alzheimer’s drug Leqembi — and as a result, broad Medicare coverage — has led to a surge in uptake, Eisai reported in its latest quarterly earnings. Now it’s about keeping up the momentum, CEO Haruo Naito said.
Eisai generated nearly $2.7 million (¥400 million) in Leqembi sales between April and September as estimated patient use increased “dramatically,” executives said on an investor call. As most Alzheimer’s patients are older, a lack of Medicare coverage proved a significant barrier to Leqembi (lecanemab) in the months following its accelerated approval.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
